MAPT and tauopathy: In contrast, 7/22 cases (32%) did not meet the neuropathological criteria of the anti-IgLON5 disease-related tauopathy due to the lack of overt/prominent brainstem tau pathology (Fig. 4), although patients had the clinical features of anti-IgLON5 disease and had anti-IgLON5 antibodies.